The EGALITY study: a confirmatory, randomized, double‐blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate‐to‐severe chronic plaque‐type psoriasis
Sign Up to like & getrecommendations! Published in 2017 at "British Journal of Dermatology"
DOI: 10.1111/bjd.15152
Abstract: GP2015 is a proposed etanercept biosimilar. read more here.
Keywords: proposed etanercept; etanercept biosimilar; gp2015 proposed; study ... See more keywords